The concept proposal, expected to be
approved at Thursday's CIRM board meeting, would fund as many as 20
grants and loans. Grants would go to nonprofit entities. Businesses
would have a choice of a loan or grant, which carry different rules
regarding intellectual property.
The translational grant proposal said two categories
would be funded:
“Research that results in a stem cell-derived development candidate (DC) to treat an unmet medical need where all necessary activities to move into IND-enabling preclinical development have been completed.
OR
“Research conducted to identify and/or establish the feasibility of a potential stem cell-derived development candidate. The goal of these development candidate feasibility (DCF) awards is to achieve preclinical (in vitro/in vivo) proof of concept. CIRM is particularly interested in proposals for DCF awards that address unique new opportunities for regenerative medicine that are potentially transformative therapeutic approaches to unmet medical needs (e.g. direct reprogramming).”
The RFA is expected to be posted in
September with funding in the summer of next year.
No comments:
Post a Comment